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Abstract
The evidence that exposure to ozone air pollution causes acute cardiovascular effects is
mixed. We postulated that exposure to ambient levels of ozone would increase blood mark-
ers of systemic inflammation, prothrombotic state, oxidative stress, and vascular dysfunc-
tion in healthy older subjects, and that absence of the glutathione S-transferase Mu 1
(GSTM1) gene would confer increased susceptibility. This double-blind, randomized, cross-
over study of 87 healthy volunteers 55–70 years of age was conducted at three sites using a
common protocol. Subjects were exposed for 3 h in random order to 0 parts per billion (ppb)
(filtered air), 70 ppb, and 120 ppb ozone, alternating 15 min of moderate exercise and rest.
Blood was obtained the day before, approximately 4 h after, and approximately 22 h after
each exposure. Linear mixed effect and logistic regression models evaluated the impact of
exposure to ozone on pre-specified primary and secondary outcomes. The definition of sta-
tistical significance was p<0.01. There were no effects of ozone on the three primary mark-
ers of systemic inflammation and a prothrombotic state: C-reactive protein, monocyte-
platelet conjugates, and microparticle-associated tissue factor activity. However, among the
secondary endpoints, endothelin-1, a potent vasoconstrictor, increased from pre- to post-
exposure with ozone concentration (120 vs 0 ppb: 0.07 pg/mL, 95% confidence interval [CI]
0.01, 0.14; 70 vs 0 ppb: -0.03 pg/mL, CI -0.09, 0.04; p = 0.008). Nitrotyrosine, a marker of
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oxidative and nitrosative stress, decreased with increasing ozone concentrations, with mar-
ginal significance (120 vs 0 ppb: -41.5, CI -70.1, -12.8; 70 vs 0 ppb: -14.2, CI -42.7, 14.2; p =
0.017). GSTM1 status did not modify the effect of ozone exposure on any of the outcomes.
These findings from healthy older adults fail to identify any mechanistic basis for the epide-
miologically described cardiovascular effects of exposure to ozone. The findings, however,
may not be applicable to adults with cardiovascular disease.
Introduction
Exposure to air pollution is a well-established risk factor for cardiovascular morbidity and
mortality. Most of the evidence supporting an association between air pollution and adverse
cardiovascular effects involves exposure to particulate matter [1]. Tropospheric ozone, formed
when nitrogen oxides and volatile organic compounds react in the lower atmosphere in the
presence of sunlight, is known to have acute respiratory effects, with decrements in lung func-
tion and increases in lung inflammation, respiratory symptoms, and respiratory mortality and
morbidity [2–4]. Recent epidemiological studies have also linked ozone exposure with
increased cardiovascular mortality and morbidity, although the evidence is mixed. For exam-
ple, Bell et al. [5] reported a 0.64% increase in the risk of cardiovascular and respiratory mor-
tality (95% confidence interval [CI] 0.31%, 0.98%) associated with each 10 parts per billion
(ppb) increase in the previous week’s ozone concentration. However, Bravo et al. [6] found no
such acute association between increased ozone concentrations and cardiovascular mortality
in the population of Sao Paulo, Brazil. Some investigators have reported increased risks of car-
diovascular and/or cerebrovascular hospital and emergency room admissions associated with
increased ozone concentrations in the days before the event [7–13], while others have not [14–
22]. Most of these studies examined associations between health outcomes and multiple ambi-
ent air pollutants.
Meta-analyses have concluded that increased ambient ozone concentrations are associated
with an increased risk/rate of stroke [23], but not myocardial infarction or heart failure [24,
25]. However, the ozone effect estimates from these meta-analyses are generally similar in
magnitude, with statistical significance reflecting in part the number of studies used. Thus,
taken together, the meta-analyses appear to support a very small increased risk of acute cardio-
vascular events associated with increased ozone concentrations in the days before the event.
Indeed, the 2013 Integrated Science Assessment for ozone prepared by the US Environmental
Protection Agency (EPA) [26], concluded there is likely a causal relationship between short-
term exposure to ozone and both total and cardiovascular mortality.
Controlled exposure studies at pollutant concentrations relevant to ambient concentrations
can explore the mechanistic basis for the associations observed in epidemiological studies
between short-term exposures to ozone and acute cardiovascular disease outcomes, and iden-
tify markers of effect that would be useful in future observational (e.g., panel) studies. Recently,
two controlled human exposure studies [27, 28] in healthy young adults, at ozone concentra-
tions sufficient to elicit changes in pulmonary function (100 ppb for 4 h and 300 ppb for 2 h,
respectively, with intermittent exercise), found effects on systemic inflammation. However,
Frampton et al. [29] found no effects of 3-h exposures to 100 and 200 ppb ozone, with inter-
mittent exercise, on measures of systemic and pulmonary vascular function, impedance cardi-
ography, blood microparticles, or blood platelet activation. Thus, findings from controlled
human exposure studies on the cardiovascular effects of ozone are inconsistent, and there are
Ozone effects in older subjects
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no studies focusing on effects in older subjects. Aging increases the risk of cardiovascular dis-
ease and may alter acute cardiovascular responses to inhaled ozone.
We postulated that initial reactions of inhaled ozone with lipid substrates on airways sur-
faces generate a variety of reactive chemicals that activate multiple airway cells. Mediators
released from these cells enter the circulation and may cause activation of blood elements,
notably platelets, and increase the production of acute phase reactants such as C-reactive pro-
tein (CRP). Activated endothelial and blood cells also generate and release membrane-
enclosed vesicles (microparticles) that contain a variety of biologically active intracellular mol-
ecules. Such vesicles may serve an endocrine-like function by adhering to other cells and trans-
ferring their contents (e.g., microparticle-associated tissue factor). These systemic changes
could result in prothrombotic as well as other cardiovascular effects.
Given that ozone exposure generates oxidative stress, individuals with impaired anti-oxi-
dant defenses may be at increased risk for acute health effects. Soluble cytosolic GSH transfer-
ases (GST) belong to a supergene family with multiple classes which might be involved in
detoxification of post-exposure inflammation-related oxidants or in the resolution of inflam-
mation. The GST Mu 1 (GSTM1) gene (reviewed by Wu et al.) [30] is particularly noteworthy
because about half the Caucasian population is genetically null for this enzyme. A controlled
human exposure study has shown an increase in the late airway inflammatory response to
ozone in GSTM1-null subjects [31, 32]. Because a prolonged inflammatory response would
increase oxidative stress, it is plausible that the GSTM1-null state might contribute to post-
ozone exposure cardiovascular changes. However, studies on the role of GSTM1 on suscepti-
bility to cardiovascular effects are few. A recent controlled ozone exposure study [29] in young
healthy volunteers did not support a role of GSTM1 in eliciting cardiac and vascular function
effects.
The Multicenter Ozone Study in oldEr Subjects (MOSES) was a controlled human exposure
study in which we exposed a relatively large number of healthy older adults, who may be more
susceptible to air pollution-induced cardiovascular health effects than younger adults [33], to
filtered air containing two levels of ozone (70 ppb and 120 ppb) and to filtered air without
ozone. The study was designed to test the hypothesis that short-term exposure to ambient lev-
els of ozone would induce acute cardiovascular responses through the following mechanisms:
autonomic imbalance, systemic inflammation, and development of a pro-thrombotic vascular
state. Secondary hypotheses were that ozone-induced acute cardiovascular responses would be
associated with a) increased systemic oxidative stress and lung effects and b) the GSTM1 null
genotype. We report here the results of MOSES with regard to blood biomarkers of systemic
inflammation and a prothrombotic state. Secondary outcomes included markers of oxidative
stress and endothelial function. Ozone effects on pulmonary and cardiovascular function in
this study are reported elsewhere [34–36].
Materials and methods
The design for MOSES has been previously described in detail [36]. The study protocol and
other study documents are available at www.healtheffects.org. Briefly, MOSES was a controlled
exposure study of the acute cardiovascular effects of ozone inhalation in healthy non-smoking
adults (ages 55 to 70 years). The study was conducted in three clinical centers: the University
of Rochester Medical Center (URMC), the University of North Carolina (UNC), and the Uni-
versity of California, San Francisco (UCSF); exposures were conducted from 2012 to 2015.
The subjects underwent 3 randomized exposure sessions, each consisting of 3 consecutive
days. At approximately noon on the first day of each session phlebotomy was performed; the
second day involved randomized exposures to clean air (0 ppb), 70 ppb, and 120 ppb ozone for
Ozone effects in older subjects
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3 h while alternately exercising and resting for 15 min, with phlebotomy 4 h after exposure;
phlebotomy was performed again on the third day, 22 h after exposure. Exposure sessions
were separated by a minimum of 2 weeks. Blood was collected from the antecubital vein of the
arm not used for other procedures, into tubes containing sodium citrate. In situ platelet and
endothelial activation were minimized by a short tourniquet time, minimizing trauma at nee-
dle entry, and discarding the first 5 mL of blood. Subjects with difficult venous access were
excluded. The subjects, investigators, and study personnel, with the exception of the individual
controlling the exposure chambers, were unaware of the nature of the exposures. The total
duration of subject participation, from the screening visit to the final visit, typically varied
between 3 and 6 months, but could be as long as 12 months. Fig 1 shows the number of sub-
jects at each stage of the study, and Fig 2 shows the timeline for each exposure session.
Subject recruitment
Written informed consent was obtained from all subjects at each clinical center. The study
was approved by the institutional review board at each center and by the US EPA Human Sub-
jects Research Review Official. A Certificate of Confidentiality was obtained from the US
Fig 1. Participant flowchart- number of subjects at each stage of the study.
https://doi.org/10.1371/journal.pone.0222601.g001
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Department of Health and Human Services. The study was registered with ClinicalTrials.gov,
Identifier NCT01487005.
Subjects were recruited through advertisements at the three clinical centers. Inclusion crite-
ria were as follows: nonsmoking males and females of all ethnic backgrounds,�55 and�70
years of age; normal spirometry (forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC)�75% of NHANES predicted values and FEV1/FVC�0.65); ability to com-
plete the training exercise regimen chosen to induce an inspired ventilation rate of 15–17 L
body temperature and pressure, saturated (BTPS) /min/m2 body surface area (BSA), without
exceeding 80% of predicted maximal heart rate; normal baseline 12-lead resting ECG, and
absence of significant ST depression while performing the 15-min required level of exercise
targeted for the exposure period; ability to avoid a specific list of medications and
supplements.
Exclusion criteria were as follows: non-English speaking; reported chronic cardiovascular
or respiratory disease, diabetes, or other organ or system dysfunction; active psychiatric disor-
ders that would interfere with the subject’s ability to understand and participate in the study;
current drug or alcohol abuse; ever-smokers (smoked tobacco or marijuana during the last
five years, or with history of>10 pack-years for tobacco or >1 joint-year for marijuana, or liv-
ing with a smoker who smokes inside the house); plasma cotinine level>3 ng/mL; body mass
index (BMI) >35 and<18; blood pressure >140 systolic or >90 diastolic or on anti-hyperten-
sion medications other than diuretics; pregnancy or nursing (breastfeeding); on the following
medications: prednisone, statins, beta-blockers, anticoagulants, current systemic estrogen
therapy, tamoxifen; and current occupational exposures to high levels of vapors, dust, gases, or
fumes.
Subjects were not studied within 6 weeks of a respiratory infection and were asked to
abstain from caffeinated and alcoholic beverages starting with lunch on the day before the
exposure through the post-exposure day.
Exposure generation and characterization
The exposures took place in ventilated, climate-controlled chambers at each of the clinical cen-
ters. The chamber characteristics and specific protocols for generating and measuring ozone
were site-specific and are described elsewhere [36].
All three centers generated ozone by silent electric-arc discharge in breathing-quality (USP
grade) oxygen from a gas cylinder. The dilution air entering the exposure chamber was puri-
fied by passing it through Purafil, charcoal, and HEPA filters. The effluent from the ozone gen-
erator was mixed with the filtered air immediately before entering the chamber. The ozone
output was controlled by varying the voltage of the generator and adjusting the flow rate. Tem-
perature and relative humidity were targeted at 22˚C and 40%, respectively. The concentration
of ozone breathed by the subject was monitored continuously during the exposure by cali-
brated and externally certified analyzers.
Fig 2. Timeline for each exposure session.
https://doi.org/10.1371/journal.pone.0222601.g002
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Outcomes
The MOSES outcomes were selected based on hypothesized cardiovascular mechanisms of
action of ozone. For each potential mechanistic pathway we identified one or more primary
outcomes (listed in bold below) and several secondary outcomes, based on either previous evi-
dence in the ozone health effects literature or clinical relevance.
In this paper, we report effects on peripheral blood biomarkers of systemic inflammation,
oxidative stress, and endothelial function (CRP, interleukin-6 [IL-6], 8-isoprostane, P-selectin,
nitrotyrosine, endothelin-1 [ET-1]), and a prothrombotic state (microparticle-associated tis-
sue factor activity [MP-TFA], von Willebrand factor (vWF), fibrinogen, and flow-cytometric
indices of platelet activation, including monocyte-platelet conjugate count, activated platelet
[CD62P+] count, platelet-derived microparticle [CD42b+] count, activated platelet-derived
microparticle [CD42b+/62P+] count, tissue factor expressing microparticle [CD142+] count,
and CD40 ligand-expressing microparticle [CD154+] count).
Assays
Microparticle-associated tissue factor activity. Plasma samples for the MP-TFA assay
were analyzed as previously described [37, 38], at the MP-TFA Core Laboratory at UNC.
Briefly, microparticles were isolated from plasma by adding 1 mL calcium-free HEPES buffer
to each 200 uL sample and pelleting at 20,000 g for 15 min at 4˚C. The pellet was washed and
resuspended in the same buffer. The MP-TF assay depends on adding calcium in the presence
of activated human factor VII (FVIIa) (Enzyme Research Lab). The TF-FVIIa complex plus
Ca++ activates added factor X (FX) (Enzyme Research Lab). The resulting FXa was then
assayed colorimetrically (absorbance at 405 nm) in the MP pellet suspension along with suit-
able controls and standards in a 96-well plate with Pefachrome FXa 8595 (Pentapharm #085–
27, Aesch, Switzerland) [37]. An essential control, the determination of TF-independent FXa
generation, in this system involved first neutralizing TF with anti-human TF antibody (HTF-
1) (Becton-Dickinson Biosciences #550252, San Jose,CA). Two plasma samples, in duplicate,
were analyzed for each subject time point. Data are reported as the average of the two
measurements.
Platelet activation and circulating microparticles. We measured blood platelet activa-
tion and circulating microparticles using immunofluorescence and flow cytometry (FC), with
modifications of methods previously reported [39]. The FC analyses were conducted at each
clinical center within 1 hour of the blood draw, on 18-color LSRII flow cytometers (Becton
Dickinson Biosciences, San Jose, CA), using the following laser options: blue 488, 515/20 nm
band pass; red 633, 620/20 nm band pass; and green 532, 575/25 nm band pass. Standardized
beads were run simultaneously with the subject samples for sizing (SORP-NIST sizing beads,
obtained by special order from Becton Dickinson), event counting (AccuCount Beads, ACBP-
20-10, obtained by special order from Spherotech, Lake Forest, IL), and fluorescence intensity
(Rainbow Beads, RCP-60-5, Spherotech). Platelets and microparticles were characterized both
unstimulated and “primed” with thrombin receptor activator peptide (TRAP)-6 (H-8365,
Bachem Americas Inc., Torrance, CA), at a concentration (2.34 μM) just below that causing
detectable activation using our methods. Marker ligand measurements included both counts
of positive events and mean fluorescence intensity of the event population. Data were collected
in list mode and sent to the Flow Core at URMC for analysis when each subject’s exposures
were completed.
The list mode data collected at each Center were analyzed using FloJo software (TreeStar,
Ashland, OR). Platelets and monocyte-platelet conjugates were analyzed using a method
adapted from Li et al. [40]. Microparticles were identified using the sizing beads and surface
Ozone effects in older subjects
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markers of the cells of origin [41]. Before starting the study, the analysis protocols and proce-
dures were developed and validated using a series of pilot blood samples from healthy volun-
teers at each study site, with analysis at the Flow Core, to assure consistent results among the
study sites. All data were analyzed at the Flow Core by the same individual. A second techni-
cian performed duplicate analyses using the same methods on complete data from three sub-
jects, one from each site, to confirm that results were not operator-dependent.
Commercial laboratory measurements. CRP, IL-6, 8-isoprostane, nitrotyrosine, fibrino-
gen, ET-1, and vWF were measured in blood plasma by the AssayGate commercial laboratory
(Ijamsville, MD). The specific assays used are described below. The laboratory utilized cus-
tom-designed antibody kits that are proprietary. The limit of detection (LOD) of each assay
was defined as the value calculated from the standard curve at the point lying 2 standard devia-
tions above the mean background media fluorescence intensity for 10 replicates.
Luminex bead-based multiplex immunoassays were used to measure CRP, fibrinogen,
vWF, IL-6, and P-selectin (Luminex1 xMAP1 technology (Austin, TX). Dilution was per-
formed for samples falling outside the range of the standard curves. Samples were tested in
duplicate. Positive controls with known analyte concentrations and negative controls on each
bead plate allowed for assay quality assurance. Sandwich enzyme-linked immunosorbent
assays (ELISA) were used to measure ET-1 and nitrotyrosine. A competitive ELISA was used
to measure 8-isoprostane. A 4-parameter standard curve was prepared relating color intensity
to the concentration of the target on each plate. Positive and negative controls on each plate
allowed for assay quality assurance.
Statistical anaysis
Power calculations for selected outcomes were performed prior to study initiation and again
during the study. Details of these analyses can be found at https://www.healtheffects.org/
system/files/MOSES-Pt1-AddtlMaterials-5.pdf.
Outcomes were calculated by subtracting the pre-exposure value from each post-exposure
value. Any of these outcome variables that were not normally distributed, via the Kolmogorov-
Smirnov test, were transformed using the natural logarithm (adding 0.001 to 0 values). This
resulted in more normal distributions of these outcomes. Outcome variables that were nor-
mally distributed were summarized using means with SDs, and those that were skewed, and
transformed as described above, were summarized using both means with SDs and medians
with inter-quartile ranges. Age was treated as a continuous value and centered by subtracting
the mean age for the cohort.
Linear mixed effect models, with a random subject effect and a ‘variance components’
covariance structure, were used to evaluate the impact of exposure to ozone on the pre-speci-
fied primary and secondary outcomes. Ozone was treated as a categorical (3-level) variable,
with clinical center and time of measurement (also categorical) included in all models. When
there was a statistically significant effect of ozone on an outcome, the ozone by time interaction
was then assessed to determine whether the ozone effect was consistent across the individual
post-exposure times. Since this study involved a large number of comparisons, we pre-speci-
fied a limited number of outcomes as primary (three of these primary variables are reported
here), and used α = 0.01 as the threshold for statistical significance, with α = 0.05 as the thresh-
old for marginal significance. Results were then interpreted within the context of coherence
among related variables, and plausibility. Significant changes in secondary variables were to be
considered hypothesis-generating but not definitive, unless there were changes consistent with
effects on the primary outcome variable(s) for that response pathway. In that case, the second-
ary variable was considered supportive of the findings for the primary variable(s). Analyses
Ozone effects in older subjects
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were performed using SAS, Version 9.3 or later (SAS Institute, Cary, NC) and R version 3.2.2
or later (The R Foundation for Statistical Computing).
Results
A total of 1,062 individuals responded to the advertisements of the three clinical centers, and
594 of these underwent telephone screening (Fig 1). Eighty-seven subjects completed all three
exposures and were included in the analyses; their characteristics are shown in Table 1. Fifty-
two (60%) were women and 35 were men. The mean (standard deviation [SD]) age of the sub-
jects was 59.9 (4.5) years. The majority of subjects (88%) identified themselves as white, with
African American being the next most common with 5 (6%). Overall, 50 (57%) of the subjects
were GSTM1 null, and the prevalence was consistent across the three centers.
Exposure conditions
The ozone concentrations in the chambers of all three centers were close to the target values.
The mean (SD) temperature was 22.3 (0.7)˚C, compared to the target of 22˚C, and the mean
(SD) relative humidity was 41.4 (3.0) %, compared to the target of 40%.
Effects of ozone on blood biomarkers
Systemic inflammation, oxidative stress, and endothelial function.
Ozone caused no change in plasma CRP, IL-6, 8-isoprostane, or P-selectin. Descriptive sta-
tistics are shown in Table 2; the distribution of values for CRP is skewed (Table 3). Linear
Table 1. Characteristics of MOSES subjects by center.
URMC (N = 32) (%) UNC (N = 29) (%) UCSF (N = 26) (%) Overall (N = 87) (%)
Gender
Male 12 (37.5) 9 (31.0) 14 (53.8) 35 (40.2)
Female 20 (62.5) 20 (69.0) 12 (46.2) 52 (59.8)
Race
American Indian 1 (3.1) 0 (0) 0 (0) 1 (1.1)
Asian 0 (0) 0 (0) 2 (7.7) 2 (2.3)
Black 1 (3.1) 4 (13.8) 0 (0) 5 (5.7)
White 28 (87.5) 25 (86.2) 23 (88.5) 76 (87.4)
Hawaiian 0 (0) 0 (0) 1 (3.8) 1 (1.1)
Unknown 1 (3.1) 0 (0) 0 (0) 1 (1.1)
GSTM1
Wild type 15 (46.9) 13 (44.8) 9 (34.6) 37 (42.5)
Null 17 (53.1) 16 (55.2) 17 (65.4) 50 (57.4)
Age (yrs) 59.1 ±3.8a 60.4 ±5.1 60.3 ±4.7 59.9 ±4.5
BMI (kg/m2) 25.0 ±2.4 24.8 ±3.7 24.8 ±3.6 24.9 ±3.2
Systolic BP (mmHg) 122.4 ±11.4 120.4 ±9.7 122.2 ±12.8 121.7 ±11.2
Diastolic BP (mmHg) 69.0 ±7.5 76.1 ±7.8 73.7 ±10.7 72.8 ±9.1
Cholesterol Total(mg/dL) 208.3 ±34.7 215.3 ±30.7 215.8 ±47.5 212.9 ±37.6
LDL Calc (mg/dL) 118.4 ±30.0 119.6 ±29.2 123.7 ±41.8 120.4 ±33.4
% predicted FEV1 104.0 ±12.8 102.4 ±13.9 102.6 ±12.9 103.0 ±13.1
URMC, University of Rochester Medical Center; UNC, University of North Carolina; UCSF, University of California San Francisco; GSTM1, glutathione S-transferase
Mu 1 gene; BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein cholesterol; FEV1, forced expiratory volume in 1 s.
aMean±SD.
https://doi.org/10.1371/journal.pone.0222601.t001
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regression analysis results are shown in Table 4. There were no statistically significant associa-
tions of ozone with any of these biomarkers, and no interactions with sex, age, or GSTM1 sta-
tus (Tables A-X in S1 Appendix). In a sensitivity analysis, there were no significant ozone
effects on CRP when subjects with baseline CRP values above the median were excluded.
Table 2. Descriptive statistics for systemic inflammatory, oxidative stress, and endothelial function outcomes.
Outcomea 0 ppb 70 ppb 120 ppb
N Mean SD N Mean SD N Mean SD
CRP (mg/L)
Pre Exposure 85 2.72 3.56 85 2.94 3.66 84 3.05 4.01
4 h Post Exposure 85 2.49 3.42 85 2.48 3.43 84 2.71 3.67
22 h Post Exposure 82 2.75 3.66 85 2.81 3.83 82 2.70 3.84
IL-6 (pg/mL)
Pre Exposure 85 3.25 3.14 85 3.26 3.03 84 3.03 2.65
4 h Post Exposure 85 3.28 2.85 85 2.84 2.21 84 2.83 2.34
22 h Post Exposure 82 3.34 2.80 85 3.31 3.33 82 2.89 2.73
8-Isoprostane (pg/mL)
Pre Exposure 85 61.65 30.12 85 61.07 31.49 84 61.99 33.72
4 h Post Exposure 85 57.98 27.13 85 55.38 25.11 84 59.55 30.86
22 h Post Exposure 82 63.00 32.74 85 59.89 28.69 82 60.40 26.29
P-selectin (ng/mL)
Pre Exposure 85 68.59 76.95 85 69.93 69.88 84 65.43 55.57
4 h Post Exposure 85 63.09 48.74 85 55.62 35.02 84 62.10 41.30
22 h Post Exposure 82 116.71 285.96 85 77.06 85.65 82 84.26 141.08
Nitrotyrosine (nM)
Pre Exposure 85 621.6 885.8 85 641.0 1066.7 84 606.5 807.2
4 h Post Exposure 85 629.3 905.2 85 659.1 1169.0 84 592.9 758.6
22 h Post Exposure 82 678.0 1010.3 85 647.6 1138.5 82 514.9 437.0
ET-1 (pg/mL)
Pre Exposure 85 1.27 0.42 85 1.26 0.35 84 1.18 0.40
4 h Post Exposure 85 1.24 0.43 85 1.22 0.36 84 1.24 0.47
22 h Post Exposure 82 1.23 0.51 85 1.17 0.40 82 1.20 0.44
Fibrinogen (μg/mL)
Pre Exposure 85 1649.4 2270.0 85 1790.0 2118.4 84 1319.0 1304.7
4 h Post Exposure 85 1459.2 1836.7 85 1520.8 1625.4 84 1346.0 1321.3
22 h Post Exposure 82 1657.1 2069.0 85 1544.9 1795.9 82 1749.0 1864.5
CRP, c-reactive protein; IL-6, interleukin-6; ET-1, endothelin-1.
aPrimary outcome bolded.
https://doi.org/10.1371/journal.pone.0222601.t002
Table 3. Median and IQR of skewed data for CRP.
CRP (mg/L) 0 ppb 70 ppb 120 ppb
N Median IQR N Median IQR N Median IQR
Pre Exposure 85 1.51 (0.59, 3.43) 85 1.91 (0.65, 3.75) 84 1.73 (0.65, 3.17)
4 h Post Exposure 85 1.48 (0.65, 2.97) 85 1.44 (0.52, 2.87) 84 1.33 (0.67, 2.88)
22 h Post Exposure 82 1.39 (0.60, 3.60) 85 1.40 (0.63, 3.27) 82 1.45 (0.72, 3.61)
CRP, c-reactive protein.
https://doi.org/10.1371/journal.pone.0222601.t003
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Nitrotyrosine decreased after 120 ppb ozone. In linear regression analysis, ozone effects on
nitrotyrosine were marginally statistically significant (p = 0.017). As shown in Fig 3, panel B,
nitrotyrosine increased 22 hr after 0 ppb ozone exposure but decreased in a concentration-
response pattern after 70 and 120 ppb compared to 0 ppb. Nitrotyrosine was unchanged at 4
hr. We found no significant interaction of ozone with sex, age, or GSTM1 status (Tables Y-Ff
in S1 Appendix).
ET-1 increased after 120 ppb, but not after 70 ppb ozone. In linear regression analysis,
ozone effects on ET-1 were statistically significant (p = 0.008, Table 4). While there was no
change in ET-1 after 70 ppb compared to 0 ppb at either 4 h or 22 h after exposure, it increased
at both time points after 120 ppb compared to 0 ppb (Fig 3, panel A). We found no statistically
significant interactions of ozone with sex, age, or GSTM1 genotype (Tables Gg-Ll in S1
Appendix).
Prothrombotic vascular status.
Ozone exposure did not increase platelet activation. The summary statistics for each pri-
mary and secondary marker are shown in Table 5, and the model results are shown in Table 6.
There were no significant ozone effects on any of the markers of platelet activation. We found
a marginally significant interaction between ozone and age for monocyte-platelet conjugates
(p = 0.013, Tables Oo and Pp in S1 Appendix). For every 1-year increase in age, exposure to
70 ppb ozone resulted in a 2.2 lower monocyte-platelet conjugate count (95% CI, -0.7, -3.6),
and exposure to 120 ppb ozone resulted in a 1.5 lower monocyte-platelet conjugate count
(95% CI, -0.06, -3.0; p = 0.041). There was no significant interaction with sex or GSTM1
(Tables Qq-Tt in S1 Appendix).
Table 4. Main analysis: Ozone effects on systemic inflammatory, oxidative stress, and endothelial function outcomesa.
Outcomeb Ozone
(ppb)
Difference in estimatesc 95% CI Type III SS
P-value
CRP (mg/L) 120 -0.15 -0.54, 0.23 0.655
70 -0.16 -0.54, 0.23
0 --- ---
IL-6 (pg/mL) 120 -0.22 -0.73, 0.29 0.567
70 -0.25 -0.75, 0.26
0 --- ---
8-isoprostane
(pg/mL)
120 -0.88 -5.87, 4.10 0.749
70 -1.91 -6.85, 3.04
0 --- ---
P-selectin
(ng/mL)
120 -14.06 -42.37, 14.26 0.235
70 -24.28 -52.41, 3.85
0 --- ---
Nitrotyrosine
(nM)
120 -41.5 -70.1, -12.8 0.017
70 -14.2 -42.7, 14.2
0 --- ---
ET-1 (pg/mL) 120 0.07 0.01, 0.14 0.008
70 -0.03 -0.09, 0.04
0 --- ---
SS, sum of squares; CRP, c-reactive protein; IL-6, interleukin-6; ET-1, endothelin-1.
aLinear mixed effect models (see Methods).
bPrimary outcome bolded.
cChange from pre- to post-exposure for 120 ppb compared to 0 ppb ozone, and 70 ppb compared to 0 ppb ozone.
https://doi.org/10.1371/journal.pone.0222601.t004
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Ozone exposure did not affect circulating microparticles (MP). There were no significant
ozone effects on MP. MP expressing CD40L showed a significant ozone-sex interaction
(p<0.001, Table Aaaa in S1 Appendix), with decreases in females and increases in males fol-
lowing ozone, relative to air exposure (Fig 4). There were no significant age or GSTM1 interac-
tions for these outcomes (Tables Yyy, Zzz, Cccc, and Dddd in S1 Appendix).
Ozone exposure did not alter plasma concentrations of vWF or fibrinogen. There were no
main ozone effects on vWF (secondary outcome). We observed a marginally significant
ozone-age interaction (p = 0.018, Tables Kkkk and Llll in S1 Appendix). For every 1-year
increase in age, exposure to 120 ppb ozone resulted in a decrease of 1382 ng/mL in vWF (95%
CI, -252, -2512, p = 0.017).
Fibrinogen decreased with 70 ppb ozone (-157 ug/mL) and increased with 120 ppb ozone
(317 ug/mL) relative to 0 ppb ozone exposure, but this did not reach statistical significance
Fig 3. Effect of ozone on nitrotyrosine and ET-1. Changes from pre-exposure in (A) ET-1 and (B) nitrotyrosine for
exposures to 0, 70, and 120 ppb ozone at 4 h and 22 h post-exposure. Pre-exposure mean and standard deviation (SD)
values are shown as an insert. The whiskers represent 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0222601.g003
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Table 5. Descriptive statistics for prothrombotic vascular outcomes.
Outcomea 0 ppb 70 ppb 120 ppb
N Mean SD N Mean SD N Mean SD
Monocyte-platelet
conjugate count
Pre Exposure 78 50.1 47.7 73 47.4 42.0 76 52.9 49.7
4 h Post Exposure 78 51.2 42.6 73 44.8 31.2 76 51.0 42.2
22 h Post Exposure 74 45.1 40.1 73 42.7 27.8 74 49.7 41.9
Activated platelet count
Pre Exposure 82 20927.7 21222.8 80 18031.1 18312.0 82 19654.0 16465.4
4 h Post Exposure 81 17532.7 12192.9 79 16117.8 14006.0 82 16152.5 13679.8
22 h Post Exposure 78 20587.0 37302.4 79 15922.9 14867.4 80 16487.2 13555.2
MP-TFA (pg/mL)
Pre Exposure 84 0.149 0.170 84 0.130 0.178 86 0.154 0.201
4 h Post Exposure 84 0.147 0.192 84 0.136 0.154 86 0.177 0.199
22 h Post Exposure 80 0.143 0.150 84 0.121 0.141 84 0.152 0.159
Platelet MP count
Pre Exposure 81 5205.2 4028.4 80 5101.1 2940.9 81 5397.6 4112.5
4 h Post Exposure 80 4677.8 3207.6 79 5025.9 3619.3 81 5038.3 3314.0
22 h Post Exposure 77 4236.3 2237.8 79 4557.0 2554.8 79 4948.2 3251.6
Activated platelet MP
count
Pre Exposure 81 832.3 1076.6 80 723.0 752.1 81 763.0 561.3
4 h Post Exposure 80 686.8 620.1 79 706.8 679.5 81 685.6 448.8
22 h Post Exposure 77 590.8 415.8 79 603.3 427.4 79 668.1 422.4
CD142+MP count
Pre Exposure 80 25033.5 40847.4 80 22555.8 32787.7 80 29834.9 56386.7
4 h Post Exposure 79 22881.8 50998.0 79 15907.7 20139.5 80 20071.2 31808.0
22 h Post Exposure 76 15082.1 23611.4 79 17851.5 31657.5 78 19492.0 28543.7
CD40 Ligand+ MP count
Pre Exposure 80 33283.4 57668.5 80 32007.5 48664.5 80 37502.8 66018.2
4 h Post Exposure 79 30629.2 60380.1 79 23561.1 31098.3 80 24390.1 31387.4
22 h Post Exposure 76 21909.8 30699.2 79 20977.3 23635.2 78 26681.8 36682.2
Platelet count (1000/uL)
Pre Exposure 84 236.8 51.8 85 237.2 59.3 85 233.9 51.3
4 h Post Exposure 83 231.4 48.5 85 230.7 61.2 84 228.8 52.3
22 h Post Exposure 80 230.3 54.9 85 226.7 61.5 81 225.9 52.7
vWF (ng/mL)
Pre Exposure 85 23774.0 24127.0 85 22101.0 26088.1 84 22450.3 21076.3
4 h Post Exposure 85 23606.5 26519.2 85 23198.3 26646.7 84 21234.9 19271.9
22 h Post Exposure 82 24703.3 25631.4 85 22359.2 36850.5 82 21645.4 24122.8
Fibrinogen (μg/mL)
Pre Exposure 85 1649.4 2270.0 85 1790.0 2118.4 84 1319.0 1304.7
4 h Post Exposure 85 1459.2 1836.7 85 1520.8 1625.4 84 1346.0 1321.3
22 h Post Exposure 82 1657.1 2069.0 85 1544.9 1795.9 82 1749.0 1864.5
MP-TFA, microparticle-associated tissue factor activity; MP, microparticles; vWF, von Willebrand factor.
aPrimary outcomes are bolded.
https://doi.org/10.1371/journal.pone.0222601.t005
Ozone effects in older subjects
PLOS ONE | https://doi.org/10.1371/journal.pone.0222601 September 25, 2019 12 / 22
(p = 0.048). There were no significant age, sex or GSTM1 interactions (Tables Qqqq-Vvvv in
S1 Appendix). Fibrinogen levels were 575 μg/mL higher (CI: 6, 1144) in GSTM1 null subjects,
independent of ozone exposure.
Discussion
In this study, we tested the hypothesis that short-term exposure of healthy older adults to near-
ambient levels of ozone would induce systemic inflammation leading to endothelial dysfunc-
tion and development of a pro-thrombotic vascular state. We chose to study older subjects,
postulating that ozone effects would be more likely to lead to acute cardiovascular effects in
older than younger subjects. We also postulated that the GSTM1 null genotype would modify
responses to ozone exposure. In this panel of 55–70 year-old healthy subjects, we found little
Table 6. Main analysis: Ozone effects on prothrombotic vascular outcomes.
Outcomea Ozone
(ppb)
Estimatesb 95% CI Type III SS
P-value
Monocyte-platelet
conjugates (count)
120 -0.2 -6.8, 6.4 0.873
70 -1.6 -8.3, 5.0
0 --- ---
Activated platelets
(count)
120 -1437.3 -5686.6, 2812.0 0.781
70 -314.3 -4591.6, 3962.1
0 --- ---
MP-TFA (pg/mL) 120 0.009 -0.030, 0.048 0.772
70 -0.005 -0.044, 0.034
0 --- ---
Platelet MP (count) 120 213.7 -382.6 810.0 0.524
70 341.7 -256.9, 940.3
0 --- ---
Activated platelet
MP (count)
120 75.3 -92.6, 243.2 0.514
70 92.9 -75.7, 261.5
0 --- ---
CD142+ MP (count) 120 -4444.2 -12932.0, 4043.6 0.551
70 -927.1 -9418.6, 7564.3
0 --- ---
CD40L MP (count) 120 -6516.9 -15307.0, 2273.6 0.306
70 -5186.7 -13984.0, 3610.7
0 --- ---
Platelet count
(1000/uL)
120 1.3 (-1.7,4.4) 0.190
70 -1.5 (-4.5,1.6)
0 --- ---
vWF (ng/mL) 120 -1527.6 -6719.4, 3664.2 0.765
70 246.3 -4913.4, 5406.0
0 --- ---
Fibrinogen (ug/mL) 120 317.3 -67.8, 702.4 0.048
70 -157.3 -539.9, 225.4
0 --- ---
MP-TFA, microparticle-associated tissue factor activity; MP, microparticles; vWF, von Willebrand factor.
aPrimary outcomes are bolded.
bChange from pre- to post-exposure for each ozone concentration, compared to 0 ppb.
https://doi.org/10.1371/journal.pone.0222601.t006
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evidence of effects of controlled exposure to low levels of ozone on a battery of peripheral
venous blood biomarkers of systemic inflammation, oxidative stress, endothelial function, and
pro-thrombotic state.
Systemic inflammation, oxidative stress, and endothelial function
Chronic inflammation has been implicated in the pathogenesis of atherosclerosis and CRP is
the inflammatory biomarker that has been most consistently associated with cardiovascular
disease risk [42]. It is an acute-phase protein that is produced in the liver in response to pro-
inflammatory cytokines, in particular IL-6. It is considered a non-specific marker of inflamma-
tion and the mechanism by which CRP contributes to cardiovascular disease risk is unknown.
Several controlled human exposure studies have documented that inhaled ozone at high
ambient concentrations can cause airway inflammation characterized by increased neutrophils
and pro-inflammatory cytokines in bronchoalveolar lavage or sputum [4, 43]. It is reasonable
to suspect that ozone-induced lung inflammation might “spill over” into the systemic circula-
tion, and some data exist to support this concept. A study of pre-exposure levels of serum IL-6
among 45 participants in controlled human exposure studies, in relation to ambient pollutant
concentrations in Toronto, reported a positive association between IL-6 and ozone, with the
strongest association using a 4-day moving average (~30 ppb) in the summer [44]. Serum CRP
increased in two recent controlled human exposure studies in which the ozone concentration
ranged from 100–300 ppb [27, 28]. CRP increased after exposure to 200 ppb but not 100 ppb
in the Arjomandi et al. study, and only relatively late (18–24 hours) after exposure in both
studies. The mean of the pre-exposure levels of CRP in the MOSES study was higher than that
reported in those two studies (2.6 mg/L versus 0.6–0.7 mg/L), likely reflecting the older age of
our subjects. A sensitivity analysis, using only subjects whose pre-exposure values were below
the median of 1.5 mg/L, did not change the results.
Oxidative stress represents an imbalance between the formation of reactive oxygen species
in a tissue and that tissue’s antioxidant capacity to detoxify the reactive intermediates. Oxida-
tive stress has been implicated in the pathogenesis of atherosclerosis and has been suggested as
a risk factor for adverse cardiovascular outcomes [45]. Ozone is a highly reactive oxidant gas
Fig 4. Effect of ozone on CD40 ligand MP count by sex. Changes from pre-exposure across 0, 70, and 120 ppb
exposure sessions at 4 h and 22 h post-exposure in females and males.
https://doi.org/10.1371/journal.pone.0222601.g004
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that can increase oxidative stress in the lung. There are both epidemiological and controlled
human exposure data to support increased systemic oxidative stress after ozone exposure [46,
47]. 8-isoprostane, a product of lipid peroxidation, has been used as a marker of oxidative
stress in previous studies [48, 49].
Based on these data, we hypothesized that ozone exposure would increase serum levels of
IL-6, CRP and 8-isoprostane. However, our results showed no evidence of an effect of ozone at
either 70 or 120 ppb on these biomarkers of inflammation and oxidative stress. A potential rea-
son for the difference between MOSES results and those of previous controlled human exposure
studies is that MOSES subjects were 55–70 years of age while previous studies recruited young
adults. Another potential reason is the higher inhaled dose of ozone to which the young adult
subjects were exposed in previous studies. It is also possible that our earliest plasma 8-isopros-
tane measurement, 4 h post-exposure, missed an earlier, transient effect of ozone exposure.
However, this time point was selected based on the significant increase reported [46] after expo-
sure of young adults to 200 ppb over 4 h with intermittent exercise. Nonetheless, given that we
measured only one biomarker of lipid peroxidation (8-isoprostane), in plasma only (measure-
ment in urine or exhaled breath condensate are alternative approaches), we cannot exclude the
possibility of ozone-induced systemic oxidative stress in exercising older subjects.
Nitrotyrosine is a product of tyrosine nitration mediated by reactive nitrogen species such
as peroxynitrite anion and NO. Oxidative stress increases the production of superoxide anion
and NO, forming peroxynitrite, a highly reactive free radical oxidant capable of oxidizing lipo-
proteins and nitrating protein tyrosine residues. Nitrotyrosine is easier to measure than perox-
ynitrite and is used as a marker of NO-dependent, reactive nitrogen species-induced nitrative
stress. To our knowledge, MOSES is the first controlled human exposure study of ozone to
measure plasma nitrotyrosine. In a mouse model, increased nitrotyrosine residues in the lung
after ozone exposure were shown to be an inducible NO synthase (NOSII)-dependent
response [50]. We hypothesized that ozone would increase nitrotyrosine; however its concen-
tration surprisingly decreased with increasing ozone concentrations, with marginal statistical
significance. As shown in Fig 3B, nitrotyrosine decreased slightly 4 hr after 120 ppb ozone, and
decreased relative to 0 ppb with increasing ozone concentrations 22 hr after exposure. How-
ever, the only change in which the 95% CI did not include 0 was the increase 22 hr after expo-
sure to 0 ppb ozone. It is possible this increase was spurious, and the relative decreases after 70
and 120 ppb represent regression to the mean. Taken together with the marginal significance
and direction of change opposite of that hypothesized, we cannot conclude that there were sig-
nificant effects of ozone exposure on nitrotyrosine. However, it is possible that reduction in
nitrotyrosine levels could be caused by ozone-induced upregulation of antioxidant systems
and pathways, quenching reactive nitrative stress.
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide originally isolated from endothelial
cells that is now known to be produced by multiple cell types when stimulated, and has been
linked to air pollution exposure [51–53]. To our knowledge, ET-1 has not been previously
evaluated as an outcome in a controlled human exposure study of ozone. Based on previous
reports of the biological effects induced by ET-1 including vasoconstriction, pro-inflammatory
responses, mitogenesis, cell proliferation, stimulation of free radical formation, and platelet
activation [54], we hypothesized that ozone exposure would increase ET-1. This was con-
firmed, with a significant overall ozone effect on ET-1 (p = 0.008). While we found no change
in ET-1 after 70 ppb at either 4 or 22 h after exposure, we did observe a marginally statistically
significant increase after 120 ppb (p = 0.028). Endothelin-1 has important interactions with
NO and is involved in the development of endothelial dysfunction. Increased production of
ET-1 and its receptors may contribute to the pathogenesis of atherosclerosis [55]. However, as
reported elsewhere [35], there was no effect of ozone exposure on blood pressure or forearm
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flow-mediated dilatation in this study, so the significance of the increase in ET-1 is uncertain.
It is possible that the vasoconstrictive effect of increased ET-1 was countered by increases in
vasodilators that were not measured, such as NO or prostanoids.
Prothrombotic vascular status
Increased propensity for vascular thrombosis has been posited as one of the pathways by
which exposure to air pollution leads to adverse cardiovascular events. We found no convinc-
ing evidence for ozone effects on platelet activation, circulating MP, or MP-TFA. We did find
a significant ozone-sex interaction for CD40L+ MP, which decreased in females and increased
in males following ozone, compared with air exposure, suggesting this response to ozone expo-
sure may differ by sex. However, none of the other thrombosis markers supported an ozone
effect or sex interaction, so we conclude there is no effect on prothrombotic vascular status at
these ozone exposure levels in this population.
A few other controlled human exposure studies have examined ozone effects on markers of
coagulation or thrombosis, with variable results. Frampton et al. [29] exposed younger, healthy
subjects to 0, 100, and 200 ppb ozone for 3 h, with intermittent exercise. There were no signifi-
cant effects on platelets or circulating microparticles 4 h after exposure, using methods similar
to those in the present study. Devlin et al. [28] exposed healthy subjects to 0 and 300 ppb for 2
h with intermittent exercise. They found no effects on plasma levels of vWF or D-dimer. Plas-
minogen levels increased 24 h after air exposure but decreased after ozone exposure. They also
reported a statistically significant increase in tissue plasminogen activator (tPA) and a signifi-
cant reduction in plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tPA, 24
h after ozone exposure, relative to air. These findings indicate possible activation of fibrinolysis
following ozone exposure, rather than the hypothesized prothrombotic effect.
Arjomandi et al. [27] found no effects of exposure to 100 and 200 ppb ozone on fibrinogen,
PAI-1, prothrombin time, partial thromboplastin time, or platelet count. Similarly, Barath
et al. [56] found no effects of 300 ppb ozone for 75 min, with intermittent exercise, on tPA or
PAI-1 following brachial arterial infusion of bradykinin, 2 and 6 h after exposure to ozone.
A recent controlled human exposure study examined the effect of varying temperature on
the effects of ozone exposure [57]. Healthy volunteers were exposed to 0 and 300 ppb ozone
for 2 h with intermittent exercise, at two different ambient temperatures. At 22˚C, PAI-1
decreased 52%, plasminogen decreased 12%, and D-dimer increased 18%. In contrast, at
32.5˚C, PAI-1 increased 45% and plasminogen increased 28%. D-dimer decreased 12.5%. This
suggested that the fibrinolytic pathway is impaired following ozone exposure at the lower tem-
perature and activated at the higher temperature.
A few panel studies have examined the effects of ozone exposure on propensity for throm-
bosis, but the findings are also mixed. Strak et al. [58] obtained blood from young healthy vol-
unteers at five different locations with varying pollutant concentrations. Intrinsic thrombin
generation was associated with increased exposures to nitrogen dioxide, nitrates, and sulfates,
but not to ozone. In 76 young, healthy subjects in Taiwan, increased ozone exposure was asso-
ciated with increased fibrinogen and PAI-1, which held up in two-pollutant models [47]. Liao
et al. [59] examined data from the ARIC study that included 10,208 middle-aged people, and
found ozone exposure was associated with increases in fibrinogen and vWF levels, with greater
effects in people with diabetes and cardiovascular disease.
A weight-of-evidence review [60] described evidence from controlled human exposure
studies for small increases in markers of inflammation and oxidative stress in response to
ozone exposure, but found no consistent effects on blood coagulation in either clinical or epi-
demiological studies.
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Strengths and limitations
This multi-center study has a number of strengths. It is one of the largest controlled human
exposure studies of ozone to be conducted to date, providing greater statistical power than pre-
vious studies. The study was designed to comprehensively evaluate the mechanistic pathways
by which air pollutants may contribute to acute cardiovascular toxicity.
The lack of exposure to a higher inhaled dose of ozone limits comparability to the previous
controlled exposure studies described above. We cannot therefore generalize the absence of
blood biomarker effects to populations exposed to higher concentrations. Also, since we stud-
ied acute responses to short-term ozone exposures, we cannot exclude the possibility of effects
of chronic or repeated exposures, or effects delayed longer than 22 h after exposure.
The chamber ozone exposure levels of 120 ppb and 70 ppb used in MOSES were only slightly
higher than peak ambient ozone levels occurring at the study centers on some days during the
study periods. Thus, it is possible that ambient ozone and other pollutant exposures experienced
by the study subjects before and during the study may have independently impacted the study
biomarkers, and/or modified, blunted, or lessened any biomarker responses to the controlled
ozone exposures. These questions are being examined and will be published separately.
By design, we restricted the participants to older, healthy subjects, who were physically fit
enough to complete the exercise regimen, and the findings may not be representative of people
in other age groups. People with pre-existing cardiovascular disease may differ in their
responses to ozone exposure. The choice to study older subjects was based on the hypothesis
that these individuals would be at increased risk for acute cardiovascular effects of ozone, but
younger individuals are known to be more responsive to the effects of ozone on lung function,
and could also be more responsive to cardiovascular effects.
Subject to the same limitations, other data from the MOSES study also failed to reveal sig-
nificant acute effects on cardiovascular function [35], although there were significant acute
changes in respiratory system parameters [34].
Summary and conclusions
In this multicenter clinical study of older healthy subjects, ozone exposure caused no effects on
systemic inflammation. Blood levels of nitrotyrosine decreased with ozone exposure with mar-
ginal statistical significance, the opposite of our hypothesis. Blood levels of the potent vasocon-
strictor, ET-1, increased with ozone exposure. The results of our study do not support acute
effects of low-level ozone exposure in healthy older subjects on systemic inflammation, oxida-
tive stress, or a pro-thrombotic state. We cannot exclude the possibility of effects with higher
ozone exposure concentrations or more prolonged exposure, or the possibility that subjects
with underlying vascular disease, such as hypertension or diabetes, would show effects under
these conditions.
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